Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …
cells from exhausted status and revive immune response against cancer cells. Based on the …
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
JR Brahmer, H Abu-Sbeih, PA Ascierto… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
[HTML][HTML] Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong… - … journal of oncology, 2021 - spandidos-publications.com
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Antitumour immunity regulated by aberrant ERBB family signalling
S Kumagai, S Koyama, H Nishikawa - Nature Reviews Cancer, 2021 - nature.com
Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
ZD Shi, K Pang, ZX Wu, Y Dong, L Hao… - … and Targeted Therapy, 2023 - nature.com
Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …
[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung …
RJ Hartmaier, AA Markovets, MJ Ahn, LV Sequist… - Cancer discovery, 2023 - AACR
MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could
overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib …
overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib …